Skip to content
Live funding
↑Coherence Quantum €2.8M Seed round led by Lifeline Ventures ↑Plinto €2.9M Pre-seed round led by People Ventures ↑Huppa €1M raises a Pre-seed round ↑XRlabs €7.3M Seed round led by Playground Global ↑Nouscom €120M Series D+ round led by M Ventures ↑Linkener €7.5M funding round led by Klima Energy Transition Fund (Alantra) ↑CoComply €2.3M funding round led by NPIF II - Mercia Equity Finance ↑Vessla €3.0M Pre-seed round led by Seedcamp ↑Neonomics €3.6M raises a funding round ↑unravel health €3.0M Pre-seed round led by Conduit EIS Impact Fund ↑Microbiotica €42.7M Series C round led by British Business Bank ↑Elevatry €3M raises a Pre-seed round ↑OMass Therapeutics €276.1M Series C round led by Bain Capital Life Sciences ↑Goodweek €10.7M funding round led by Adara Ventures ↑Qilimanjaro Quantum Tech €19.6M raises a Series A round ↑Ambio €5.1M Seed round led by Lifeline Ventures ↑Duvo €28.5M Series A round led by Balderton Capital ↑Salience Labs €111.4M Series B round led by Bullhound Capital ↑Wavo €10M funding round led by Eurazeo ↑Cofrai €2.6M funding round led by DFF Ventures
Sesame Summit 2027
Sesamers
Selected · Episode 35 · April 13, 2023

Pedro Correa de Sampaio - bacteria against tumours

Neobe Therapeutics co-founder Pedro Correa de Sampaio on engineering bacteria to break down tumour matrix so cancer immunotherapies reach resistant patients.

0:0028 min

About this episode

1. The Genesis of Neobe Therapeutics: Pedro co-founded Neobe Therapeutics with the aim of addressing a significant issue in the pharmaceutical industry: drug resistance in cancer treatment. Approximately 20% of cancer patients don't respond to immunotherapies, which are drugs that activate an immune response against cancer. And that is the problem Pedro & his team are trying to solve - making these drugs work in more patients by breaking down their extracellular matrix. Neobe Therapeutics' groundbreaking approach involves using engineered bacteria to overcome drug resistance, offering hope for more effective treatment options.

Get the weekly briefing Europe's rounds, founders & events - every Monday, in five minutes.